CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
复制标题
DOI：
10.1182/blood.v95.4.1502.004k40_1502_1505
复制
发表时间：
2000-02-15
期刊：
影响因子：
20.3
通讯作者：
Heslop, HE
中科院分区：
文献类型：
--
作者：
Kuehnie, I;Huls, MH;Heslop, HE
骨髓移植(BMT)后，使用来自非血缘供者或人类白细胞抗原不匹配的血缘供者的T细胞耗尽的骨髓，发生与EB病毒(EBV)相关的淋巴增殖性疾病的风险从1%到25%不等。我们已经证明，供者来源的EBV特异性细胞毒性T淋巴细胞(CTL)是这种并发症的有效预防和治疗方法，我们经常为高危患者产生CTL。然而，EBV淋巴瘤可以发生在配对同胞移植的受者中，对于这些受者来说，CTL是不可用的，或者是在CTL治疗是禁忌的患者中。我们报告了3例这样的患者，他们成功且安全地使用了CD20单抗利妥昔单抗治疗。患者分别在治疗后7、8和9个月保持无病状态。我们得出结论，CD20抗体可能是骨髓移植后EBV淋巴瘤患者的一种有用的替代治疗策略。(C)2000年，由美国血液病学会提供。
After bone marrow transplantation (BMT) using T-cell-depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-specific cytotoxic T lymphocytes (CTL) is effective prophylaxis and treatment for this complication, and we routinely generate CTL for high-risk patients. However, EBV lymphoma can occur in recipients of matched-sibling transplants for whom CTL are unavailable or in patients for whom CTL administration is contraindicated. We report on 3 such patients, who were successfully and safely treated with rituximab, a CD20 monoclonal antibody. The patients remain disease free 7, 8, and 9 months, respectively, after therapy. We conclude that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT. (C) 2000 by The American Society of Hematology.